Every 8-K that Chemed Corporation (CHE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CHE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CHE filings page.
Chemed Corporation reported stronger Q2 2026 results, with service revenues and sales of $673,251 thousand and net income of $67,703 thousand, or $5.13 per diluted share, up from $3.57 a year earlier. Adjusted diluted EPS rose to $6.06 from $4.27.
VITAS net revenue increased 11.9% to $443.3 million, driven by higher days-of-care, modest Medicare reimbursement increases, sharply lower Medicare Cap billing limitations, and 9.0% higher admissions. Roto-Rooter revenue grew 3.3% to $229.9 million, with gross margin improving to 50.4%.
On this performance and substantial share repurchases, Chemed raised full-year 2026 adjusted EPS guidance to $25.00–$25.75 per diluted share, compared with prior guidance of $24.00–$24.75; the midpoint is 17.8% above 2025 adjusted EPS of $21.55.
Chemed Corporation reported voting results from its annual meeting of stockholders held on May 18, 2026. All director nominees were elected, with support levels generally above ten million votes for each candidate and broker non-votes of 769,580 on each director item.
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent accountants for the year ending December 31, 2026, with 11,562,294 votes for and 523,129 against. However, the non-binding proposal to approve the company’s executive compensation program was not approved, receiving 4,383,683 votes for and 6,926,656 votes against, with 769,580 broker non-votes.
Chemed Corporation reported first-quarter 2026 revenue of $657.5 million, up slightly from $646.9 million a year earlier, with net income of $66.3 million and diluted EPS of $4.84 versus $4.86. Adjusted diluted EPS rose to $5.65 from $5.63.
VITAS revenue grew 3.1% to $420.0 million, driven by 2.2% higher days-of-care and Medicare rate increases, while Roto-Rooter revenue slipped 0.9% to $237.5 million and its adjusted EBITDA margin fell. Chemed bought San Francisco and Fort Worth Roto-Rooter franchises for $20.6 million and repurchased 500,000 shares for $197.7 million.
Management raised full-year 2026 guidance, now expecting adjusted EPS of $24.00–$24.75, whose midpoint is a 13% increase over 2025’s $21.55 and above the prior 2026 range of $23.25–$24.25. VITAS growth and margins were revised upward, while Roto-Rooter’s adjusted EBITDA margin outlook was trimmed due to higher marketing costs.
Chemed Corporation entered into a new five-year $450 million senior secured revolving credit facility, documented in a Sixth Amended and Restated Credit Agreement. The facility includes a $100 million letters of credit sublimit and an accordion feature of up to $250 million in additional revolving capacity.
Borrowings bear interest at a floating rate based on the secured overnight financing rate (SOFR) plus a tiered margin that depends on Chemed’s leverage ratio. JPMorgan Chase Bank serves as Administrative Agent and Joint Lead Arranger, with Bank of America, PNC Bank and U.S. Bank in key syndicate roles.
Chemed Corporation reported mixed fourth-quarter 2025 results and issued 2026 guidance. Q4 service revenues and sales were $639.3 million, essentially flat year over year, while net income declined to $76.8 million from $90.3 million. Diluted EPS fell to $5.48 from $6.02.
VITAS net revenue grew 1.9% to $418.8 million, supported by higher days-of-care and Medicare reimbursement, though gross margin excluding Medicare Cap fell to 27.3%. Roto-Rooter revenue declined 3.7% to $220.6 million, and adjusted EBITDA dropped 21.1% with margin down to 21.5%.
For full-year 2025, Chemed generated service revenues and sales of $2.53 billion and net income of $265.2 million, or $18.34 diluted EPS. Adjusted diluted EPS was $21.55. The company ended 2025 with $74.5 million in cash, no debt, and repurchased 400,000 shares for $174.6 million.
Management expects 2026 VITAS revenue to grow 5.5%–6.5% before Medicare Cap and Roto-Rooter revenue to grow 3.0%–3.5%. Adjusted diluted EPS is projected between $23.25 and $24.25, above 2025’s $21.55, with about 55% of adjusted earnings and EBITDA weighted to the year’s second half.
Chemed Corporation filed a current report stating that on October 28, 2025 it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company notes that this press release is furnished as Exhibit 99 to the report, making the detailed quarterly results available through that exhibit.
Chemed Corporation (NYSE: CHE) filed a Form 8-K on June 27, 2025 to furnish a Regulation FD disclosure.
- Material event: The Company issued a press release (Exhibit 99) stating it now expects second-quarter 2025 earnings to be lower than previously anticipated and is reducing its full-year 2025 earnings guidance.
- The filing does not include specific dollar amounts, revised EPS figures or updated revenue ranges; only the direction of the change is disclosed.
- No other operational changes, financings, or acquisitions were reported in the filing.
- The press release itself is furnished, not filed, preserving safe-harbor protections for forward-looking statements.
Because the Company is signalling weaker performance and a downward revision to outlook, the disclosure is materially negative for investors, implying potential pressure on near-term financial results and valuation multiples. Investors will need to review the full press release and forthcoming Q2 results to quantify the impact.